Humana (NYSE:HUM) Reaches New 12-Month Low at $297.57

Humana Inc. (NYSE:HUM)’s stock price hit a new 52-week low on Tuesday . The company traded as low as $297.57 and last traded at $300.17, with a volume of 1849842 shares trading hands. The stock had previously closed at $316.74.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HUM shares. Truist Financial upped their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. increased their target price on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft increased their target price on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Piper Sandler initiated coverage on Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 target price on the stock. Finally, Royal Bank of Canada increased their target price on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, September 5th. Thirteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $398.70.

Humana Stock Performance

The firm has a market capitalization of $33.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.44 and a beta of 0.50. The company has a fifty day moving average of $348.57 and a two-hundred day moving average of $344.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm posted $8.94 EPS. As a group, equities research analysts predict that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.27%. Humana’s payout ratio is 22.04%.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. grew its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Hantz Financial Services Inc. bought a new stake in Humana during the 2nd quarter worth $35,000. Family Firm Inc. bought a new stake in Humana during the 2nd quarter worth $37,000. Hollencrest Capital Management bought a new stake in Humana during the 2nd quarter worth $40,000. Finally, Riverview Trust Co bought a new stake in Humana during the 2nd quarter worth $44,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.